Alnylam Pharmaceuticals, Inc. vs Wayfair Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.14 (market cap $29.60B), while Wayfair Inc trades at $104.53 (market cap $14.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.1× Wayfair Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | W | |
|---|---|---|
Market Cap | $29.60B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $119.05 |
52-Week Low | $205.48 | $57.40 |
Enterprise Value | $27.56B | $16.47B |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Wayfair (W) trades at $102.14, down 1.15% today but showing strong technical momentum with a recent golden cross signal. The company reported Q2 2026 earnings of $0.95 per share, beating estimates, with 7.5% revenue growth driven by U.S. market share gains. Despite negative net margins, operating cash flow improved to $665M in 2026, and analyst sentiment remains bullish with 51.8% buy ratings.
The outlook is cautiously optimistic with strong U.S. growth and margin expansion potential, but risks include persistent net losses, high debt-to-asset ratio of 95.1%, and international segment weakness. The consensus price target of $122 suggests 19% upside if execution improves.
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →